E
8.30
-0.09 (-1.07%)
| 前收盘价格 | 8.39 |
| 收盘价格 | 8.36 |
| 成交量 | 886,354 |
| 平均成交量 (3个月) | 1,276,712 |
| 市值 | 442,814,144 |
| 市盈率 (P/E TTM) | 3.17 |
| 预期市盈率 (P/E Forward) | 2.06 |
| 价格/销量 (P/S) | 0.550 |
| 股市价格/股市净资产 (P/B) | 0.810 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2025 |
| 营业毛利率 | -13.63% |
| 营业利益率 (TTM) | 22.68% |
| 稀释每股收益 (EPS TTM) | -2.58 |
| 季度收入增长率 (YOY) | -26.00% |
| 季度盈利增长率 (YOY) | 655.60% |
| 总债务/股东权益 (D/E MRQ) | 121.71% |
| 流动比率 (MRQ) | 6.32 |
| 营业现金流 (OCF TTM) | 110.10 M |
| 杠杆自由现金流 (LFCF TTM) | 91.12 M |
| 资产报酬率 (ROA TTM) | -1.61% |
| 股东权益报酬率 (ROE TTM) | -21.63% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Emergent BioSolutions Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.00 |
|
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 2.83% |
| 机构持股比例 | 67.20% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Oak Hill Advisors Lp | 30 Jun 2025 | 3,613,338 |
| 52周波幅 | ||
| 中 | 15.00 (80.72%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Sep 2025 | 15.00 (80.72%) | 购买 | 7.83 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合